4-(p-BIS(β-CHLOROETHYLAMINO)PHENYL ETHYLAMINO)-7-CHLOROQUINOLINE MONO HYDROCHLORIDE

Suppliers

Names

[ CAS No. ]:
4465-92-3

[ Name ]:
4-(p-BIS(β-CHLOROETHYLAMINO)PHENYL ETHYLAMINO)-7-CHLOROQUINOLINE MONO HYDROCHLORIDE

[Synonym ]:
N-[2-[4-[bis(2-chloroethyl)amino]phenyl]ethyl]-7-chloroquinolin-4-amine hydrochloride
Quinoline,4-(p-bis(2-chloroethyl)aminophenylethylamino)-7-chloro-,monohydrochloride
Chloroquine-ethyl phenyl mustard
Quinoline,7-chloro-4-((p-(bis(2-chloroethyl)amino)phenethyl)amino)-,monohydrochloride

Chemical & Physical Properties

[ Density]:
1.324g/cm3

[ Boiling Point ]:
607.9ºC at 760 mmHg

[ Molecular Formula ]:
C21H23Cl4N3

[ Molecular Weight ]:
459.23900

[ Flash Point ]:
321.4ºC

[ Exact Mass ]:
457.06500

[ PSA ]:
28.16000

[ LogP ]:
6.70180

[ Index of Refraction ]:
1.669

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
VB0200000
CHEMICAL NAME :
Quinoline, 4-(p-bis(2-chloroethyl)aminophenylethylamino)-7-chlor o-, monohydrochloride
CAS REGISTRY NUMBER :
4465-92-3
LAST UPDATED :
199203

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
11500 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
CCSUBJ Cancer Chemotherapy Reports, Part 2. (Washington, DC) V.1-5, 1964-75. For publisher information, see CTRRDO. Volume(issue)/page/year: 2,202,1965
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
11500 ug/kg
TOXIC EFFECTS :
Blood - other changes
REFERENCE :
CCSUBJ Cancer Chemotherapy Reports, Part 2. (Washington, DC) V.1-5, 1964-75. For publisher information, see CTRRDO. Volume(issue)/page/year: 2,202,1965

Related Compounds

  • 2-(m-tolyl)-N-(3,3,5-trimethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)acetamide
  • 2-ethoxy-N-(3,3,5-trimethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)acetamide
  • 3,4,5-triethoxy-N-(3,3,5-trimethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)benzamide
  • 3,3-dimethyl-N-(3,3,5-trimethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)butanamide
  • 3,4-difluoro-N-(3,3,5-trimethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)benzamide
  • N-(3,3,5-trimethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)-1-naphthamide
  • 2-(naphthalen-1-yl)-N-(3,3,5-trimethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)acetamide
  • 2,4-dimethoxy-N-(3,3,5-trimethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)benzamide
  • 3,4-dimethoxy-N-(3,3,5-trimethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)benzamide
  • 4-(tert-butyl)-N-(3,3,5-trimethyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-7-yl)benzamide
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.